Search
Influenza B virus B/Victoria/705/2018 BVR-11 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB15706ApprovedInvestigationalWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Mixtures: FLUAD Injektionssuspension in einer Fertigspritze, Sandovac Injektionssuspension in einer FertigspritzeDalfopristin
go.drugbank.com/drugs/DB01764ApprovedDalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Categories: Amino Acids, Peptides, and ProteinsEgg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
Mixtures: Liposyn II Inj 10%, Liposyn IITestolactone
go.drugbank.com/drugs/DB00894ApprovedWithdrawnAn antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
Influenza A virus A/Michigan/45/2015 X-275 (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14458ApprovedVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals.
Mixtures: SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.5ml, SKYCellflu Trivalent Solution for Injection in Prefilled Syringe 0.25mlMK-8189
go.drugbank.com/drugs/DB19153InvestigationalMK-8189 is under investigation in clinical trial NCT04624243 (Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)).
Synonyms: 4-PYRIMIDINAMINE, 2-METHYL-6-(((1S,2S)-2-(5-METHYL-2-PYRIDINYL)CYCLOPROPYL)METHOXY)-N-((5-METHYL-1,3,4-THIADIAZOL-2-YL)METHYL)-Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigational[A264688] Revumenib is an oral small molecule menin inhibitor that prevents the interaction between menin and aberrant KMT2A. … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.
Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-Dithiazanine
go.drugbank.com/drugs/DB11516ApprovedVet approvedWithdrawnDithiazanine iodide has been withdrawn from the market in countries such as France in Italy, but it may remain available in others.[A254427,L44032] … Dithiazanine is a highly potent anthelmintic, introduced in 1959 for the treatment of strongyloid worms and whipworms. However, its use is severely limited due to its toxicity.
Categories: Indicators and Reagents, Compounds used in a research, industrial, or household settingLuspatercept
go.drugbank.com/drugs/DB12281ApprovedInvestigational[L42455] Luspatercept is novel in that it ameliorates anemia via action on late-stage erythropoiesis, in contrast to typical erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa] and [epoetin … [A187835] Luspatercept's novel mechanism of action, then, is uniquely suited for the treatment of conditions in which late-stage erythropoiesis is defective, such as beta thalassemia and other myelodysplastic
Categories: Enzymes and Coenzymes, Blood and Blood Forming OrgansRetifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigationalBy blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. … Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating Agents